Immunic Inc (IMUX)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Immunic Inc Stock (IMUX) Company Profile

(332) 255-9818

1200 AVENUE OF THE AMERICAS, NEW YORK

Nächster Verdiensttermin

Neueste SEC-Einreichungen

IMUX's Discussions on Twitter

Immunic Inc Stock (IMUX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-10-21	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-09-19	Fortgesetzt	H.C. Wainwright	Buy
2021-04-15	Eingeleitet	Aegis Capital	Buy
2021-03-24	Eingeleitet	JMP Securities	Mkt Outperform
2020-10-02	Eingeleitet	SVB Leerink	Outperform
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-08-07	Fortgesetzt	ROTH Capital	Buy
2020-07-20	Eingeleitet	BMO Capital Markets	Outperform
2020-06-05	Eingeleitet	Wedbush	Outperform
2020-05-11	Eingeleitet	H.C. Wainwright	Buy
2020-03-25	Eingeleitet	ROTH Capital	Buy
2019-07-11	Eingeleitet	Chardan Capital Markets	Buy

Alle ansehen

Immunic Inc Aktie (IMUX) Neueste Nachrichten

Finanzdaten der Immunic Inc-Aktie (IMUX)

Immunic Inc (IMUX)

Immunic Inc Stock (IMUX) Company Profile

Immunic Inc Stock (IMUX) Upgrades & Downgrades

Immunic Inc Aktie (IMUX) Neueste Nachrichten

Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors UK

Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors USA

Immunic, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.22) Per Share (NASDAQ:IMUX) - Defense World

Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX), - Yahoo Finance

Research Analysts Offer Predictions for Immunic, Inc.'s Q3 2024 Earnings (NASDAQ:IMUX) - MarketBeat

Leerink Partnrs Upgrades Immunic (NASDAQ:IMUX) to Strong-Buy - Defense World

Immunic (NASDAQ:IMUX) Upgraded by Leerink Partnrs to "Strong-Buy" - MarketBeat

Immunic’s (IMUX) Outperform Rating Reaffirmed at Leerink Partners - Defense World

Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Australia

Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com India

Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com

Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Canada

Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com UK

Immunic, Inc. (NASDAQ:IMUX) Receives $12.75 Consensus Target Price from Analysts - MarketBeat

Immunic (NASDAQ:IMUX) Receives Outperform Rating from Leerink Partners - MarketBeat

Immunic drug targeting post-COVID syndrome in Phase 2 trialICYMI - Proactive financial news

Immunic Welcomes Jason Tardio As COO And President - Contract Pharma

Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors Australia

Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA

Immunic shares hold steady price target, overweight on MS program potential - Investing.com

Immunic shares hold steady price target, overweight on MS program potential - Investing.com India

Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA

EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - sharewise

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - PR Newswire

Immunic extends Executive Chairman's term, raises salary - Investing.com

Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com Canada

Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com UK

Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 6.3% in August - MarketBeat

There is no doubt that Immunic Inc (IMUX) ticks all the boxes. - SETE News

Immunic Inc (IMUX) shows promising results - US Post News

Immunic, Inc. (NASDAQ:IMUX) Sees Large Decrease in Short Interest - Defense World

Immunic, Inc. (NASDAQ:IMUX) to Post Q3 2024 Earnings of ($0.23) Per Share, B. Riley Forecasts - MarketBeat

Immunic to highlight lead asset’s promise at upcoming Multiple Sclerosis R&D Day - Proactive Investors UK

Market Resilience: Immunic Inc (IMUX) Finishes Weak at 1.40, Down -3.10 - The Dwinnex

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - StockTitan

Immunic initiated with a Buy at B. Riley - TipRanks

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - Yahoo Finance

B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com

Immunic (NASDAQ:IMUX) Now Covered by B. Riley - Defense World

B. Riley Initiates Coverage on Immunic (NASDAQ:IMUX) - MarketBeat

B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com India

Immunic Inc (IMUX) Stock: A Year of Market Fluctuations - The InvestChronicle

Immunic Stock (NASDAQ:IMUX): CEO Says “Right Time to Buy Now” - TipRanks

Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 8.8% in July - MarketBeat

Immunic, Inc. (NASDAQ:IMUX) Shares Purchased by Vanguard Group Inc. - MarketBeat

Vanguard Group Inc. Buys 1,703,047 Shares of Immunic, Inc. (NASDAQ:IMUX) - Defense World

Immunic, Inc.'s (NASDAQ:IMUX) Shift From Loss To Profit - Simply Wall St

Biotech Alert: Searches spiking for these stocks today - TipRanks

Immunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.com - MarketBeat

StockNews.com Upgrades Immunic (NASDAQ:IMUX) to Hold - Defense World

Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge - Barchart

Finanzdaten der Immunic Inc-Aktie (IMUX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie IMUX